234 related articles for article (PubMed ID: 23358727)
1. [Herpes zoster after varicella-zoster vaccination].
Fahlbusch M; Wesselmann U; Lehmann P
Hautarzt; 2013 Feb; 64(2):107-9. PubMed ID: 23358727
[TBL] [Abstract][Full Text] [Related]
2. [Complications in two children with acute lymphatic leukemia caused by vaccination against varicella zoster virus].
Christensen CL; Poulsen A; Böttiger B; Kirk M; Andersen HK; Schmiegelow K
Ugeskr Laeger; 1999 Feb; 161(6):794-6. PubMed ID: 10068350
[TBL] [Abstract][Full Text] [Related]
3. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child.
Uebe B; Sauerbrei A; Burdach S; Horneff G
Eur J Pediatr; 2002 Aug; 161(8):442-4. PubMed ID: 12172829
[TBL] [Abstract][Full Text] [Related]
4. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.
Barbosa CM; Terreri MT; Rosário PO; de Moraes-Pinto MI; Silva CA; Hilário MO
Clin Exp Rheumatol; 2012; 30(5):791-8. PubMed ID: 22935227
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).
Goulleret N; Mauvisseau E; Essevaz-Roulet M; Quinlivan M; Breuer J
Vaccine; 2010 Aug; 28(36):5878-82. PubMed ID: 20600487
[TBL] [Abstract][Full Text] [Related]
6. Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.
Choi UY; Huh DH; Kim JH; Kang JH
Hum Vaccin Immunother; 2016 Oct; 12(10):2560-2564. PubMed ID: 27484734
[TBL] [Abstract][Full Text] [Related]
7. The safety profile of varicella vaccine: a 10-year review.
Galea SA; Sweet A; Beninger P; Steinberg SP; Larussa PS; Gershon AA; Sharrar RG
J Infect Dis; 2008 Mar; 197 Suppl 2():S165-9. PubMed ID: 18419392
[TBL] [Abstract][Full Text] [Related]
8. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of wild-type varicella-zoster strains from India and the Oka vaccine strain using a VZV open reading frame - 62 based PCR-RFLP technique.
Kaushik KS; Lahiri KK; Kapila K; Kumar S; Gupta RM; Karade S
Braz J Infect Dis; 2008 Aug; 12(4):313-5. PubMed ID: 19030732
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.
Gershon AA; Levin MJ; Weinberg A; Song LY; LaRussa PS; Steinberg SP; Bartlett P;
Pediatr Infect Dis J; 2009 Jul; 28(7):653-5. PubMed ID: 19561431
[TBL] [Abstract][Full Text] [Related]
12. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.
Weinmann S; Chun C; Schmid DS; Roberts M; Vandermeer M; Riedlinger K; Bialek SR; Marin M
J Infect Dis; 2013 Dec; 208(11):1859-68. PubMed ID: 23922376
[TBL] [Abstract][Full Text] [Related]
13. Immune response of varicella vaccinees to different varicella-zoster virus genotypes.
Sauerbrei A; Stefanski J; Gruhn B; Wutzler P
Vaccine; 2011 May; 29(22):3873-7. PubMed ID: 21459174
[TBL] [Abstract][Full Text] [Related]
14. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
[TBL] [Abstract][Full Text] [Related]
15. Preventing varicella-zoster disease.
Hambleton S; Gershon AA
Clin Microbiol Rev; 2005 Jan; 18(1):70-80. PubMed ID: 15653819
[TBL] [Abstract][Full Text] [Related]
16. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
[TBL] [Abstract][Full Text] [Related]
17. Varicella Virus Vaccination in the United States.
Shaw J; Gershon AA
Viral Immunol; 2018 Mar; 31(2):96-103. PubMed ID: 29173081
[TBL] [Abstract][Full Text] [Related]
18. Herpes zoster after vaccination with one dose varicella vaccine to a 4-year-old child.
Pelekouda E; Papagiannis D; Tsiaousi I; Maltezou HC
Infez Med; 2019 Dec; 27(4):449-451. PubMed ID: 31846998
[TBL] [Abstract][Full Text] [Related]
19. The effect of vaccination on the epidemiology of varicella zoster virus.
Edmunds WJ; Brisson M
J Infect; 2002 May; 44(4):211-9. PubMed ID: 12099726
[TBL] [Abstract][Full Text] [Related]
20. Herpes zoster at the vaccination site in immunized healthy children.
Song H; Morley KW; Trowbridge RM; Butler DC; Liang MG; Gellis SE; Huang JT
Pediatr Dermatol; 2018 Mar; 35(2):230-233. PubMed ID: 29405375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
